Quidel Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of point-of-care (POC) diagnostic solutions for infectious diseases, and reproductive and women’s health. It provides POC and other diagnostic tests under the QuickVue, QuickVue+, QuickVue Advance, Metra, Quidel, and MicroVue brand names. The company offers products for infectious diseases, such as Influenza, Group A Strep, and Respiratory Syncitial Virus; and for reproductive and women’s health, including pregnancy, Chlamydia, Bacterial Vaginosis, and Bone Health. It also offers Immunoassay fecal occult blood test used to detect the presence of blood in stool specimens; and Helicobacter pylori test, a serological test to measure antibodies circulating in the blood caused by the immune response to the H. pylori bacterium. In addition, the company provides veterinary products; and clinical laboratory and research tests that are used in the measurement of circulating immune complexes, complement deficiencies, and complement activation. It sells its products to professionals for use in physician offices, hospitals, clinical laboratories, retail clinics, and wellness screening centers through a network of national and regional distributors, and a direct sales force in the United States, as well as through distributor arrangements primarily in Japan, Europe, and the Middle East. The company has an agreement with BioHelix Corporation for the development and commercialization of in vitro molecular diagnostic tests utilizing isothermal amplification technology. Quidel Corporation was founded in 1979 and is based in San Diego, California.
Above: Home Page
Diagnostic Hybrids To Sell For $130M In Grand Slam For Investor (fis.dowjones.com)